The former CEO of orthopedics company OtisMed, Charlie Chi, was sentenced to two years in prison. He will also face a year of supervised release and a $75,000 fine, all for distributing the OtisKnee cutting guide after the FDA denied its 510(k) application.
India may soon make scuttlebutt on medical device price controls a reality, starting with orthopedic implants, the Times of India reports, as the National Pharmaceutical Pricing Authority asks Johnson & Johnson, Zimmer and Stryker to submit details of production and pricing of their products, including those for knee and hip.
New startup LaunchPad Medical has in-licensed a bone adhesive candidate from Stryker. The company is headed by a former R&D manager at Stryker, Brian Hess, who the company named Co-Innovator of the Year in 2010 for his work on this bone adhesive, Tetranite.
The device industry is the source of wealth for 10 of the people on Forbes' annual list of the 400 richest people in America.
Stryker announced FDA clearance to use the Mako robotic surgery system for total hip replacement, as well as the launch of a new bone matrix, and spine-stabilizing cervical plate at the American Academy of Orthopaedic Surgeons Annual Meeting in Las Vegas.
The FDA is putting robot assisted surgery in the spotlight this summer.
The medical device tax is costing the med tech industry money--and so is lobbying to get rid of it.
Smith & Nephew was down 8% on the March 3 news that Stryker now has a massive $2.6 billion authorization available for share repurchases. That's a significant shift in strategy for Stryker, which has been highly acquisitive in the last few years and has long been rumored as a potential buyer for Smith & Nephew.
Stryker is signaling that it could hit the brakes on acquisitions after an aggressive string of at least a half-dozen purchases over the past few years, including the $1.7 billion purchase of robotic surgery player Mako Surgical in December 2013.
An aggressive acquisition strategy in order to broaden its product usage in trauma units and hospitals continues to be the focus for Stryker.